Nab-paclitaxel Plus Gemcitabine Seems Effective After FOLFIRINOX for Pancreatic Cancer

Share this content:
Nab-paclitaxel plus gemcitabine seems to be effective after FOLFIRINOX failure in metastatic pancreatic adenocarcinoma.
Nab-paclitaxel plus gemcitabine seems to be effective after FOLFIRINOX failure in metastatic pancreatic adenocarcinoma.

Nab-paclitaxel plus gemcitabine seems to be effective, with a manageable toxicity profile, after FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) failure in patients with metastatic pancreatic adenocarcinoma, a new study published online ahead of print in the British Journal of Cancer has shown.1

Because there is currently no standard second-line treatment for metastatic adenocarcinoma, and progression-free survival is often less than 4 months in this setting, researchers sought to evaluate the efficacy and tolerability of nab-paclitaxel plus gemcitabine after FOLFIRINOX failure.

Researchers enrolled 57 patients with histologically proven metastatic pancreatic adenocarcinoma after failure of FOLFIRINOX treatment.

All received nab-paclitaxel plus gemcitabine until disease progression, patient refusal, or unacceptable toxicity. Patients received treatment for a median of 4 cycles.

Results showed that the disease control rate 58%, with an objective response rate of 17.5%. Researchers found that the median overall survival was 8.8 months (95% CI: 6.2-9.7) and median progression-free survival was 5.1 months (95% CI: 3.2-6.2).

RELATED: Focused Electrical Blasts Following Chemo May Increase Survival in Pancreatic Cancer Patients

The study demonstrated a median overall survival since the initiation of first-line chemotherapy of 18 months (95% CI: 16-21).

In regard to safety, grade 3 to 4 toxicities were reported in 40% of patients. The most common grade 3 to 4 adverse events were neutropenia, neurotoxicity, asthenia, and thrombocytopenia.

Reference

  1. Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. [published online ahead of print September 15, 2015]. B J Cancer. doi: 10.1038/bjc.2015.328.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs